Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-LUNG01)
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Datopotamab deruxtecan (Primary) ; Docetaxel
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms TROPION-LUNG01
- Sponsors Daiichi Sankyo Inc
- 09 Jul 2024 Planned End Date changed from 27 Jun 2024 to 21 Jun 2025.
- 30 May 2024 This trial has been completed in Czechia, according to European Clinical Trials Database record.
- 27 May 2024 Results presented in an AstraZeneca Media Release.